Group Head Quantitative Safety and Epidemiology
Novartis Pharma AG, Switzerland
Elodie Aubrun is Group Head of Quantitative Safety and Epidemiology (QSE), working at Novartis since August 2018, and increased her responsibilities in her role and led the pre- and post-marketing epidemiology strategy for several products in Respiratory, Global Health and Immunology, Hepatology & Dermatology. She was a key contributor to the internal initiative on use of Registries, and she is a member of CIOMS working group XIII on Real World Evidence.
Before joining Novartis, Elodie was Associate Director, Epidemiology and Outcome Research, at IQVIA. She had 10 years of experience in pharmacoepidemiology within pharma companies and contract research organizations, where she worked in different therapeutic areas such as psychiatry, internal medicine, neurology, cardiology and others, and gained insight and expertise in designing, conducting and reporting observational studies.
Elodie received her MSc (focus on medicine and health products: impact on public health, market access, safety assessment) from CNAM, Conservatoire national des Arts et metiers, Paris, France, and holds a PharmD and MPH from University Paris XI, France.
